ストックスクリーナーアプリを入手
59.18
27.71%
12.84
プレマーケット:
60.50
1.32
+2.23%
前日終値:
$46.34
開ける：
$47.53
24時間の取引高:
42.61M
Relative Volume:
2.72
時価総額：
$12.93B
収益：
$1.24B
当期純損益:
$101.26M
株価収益率:
134.50
EPS:
0.44
ネットキャッシュフロー:
$149.62M
1週間 パフォーマンス:
+46.23%
1か月 パフォーマンス:
+128.49%
6か月 パフォーマンス:
+270.34%
1年 パフォーマンス:
+524.26%
1日の値動き範囲:
$47.14
$59.55
1週間の範囲:
$41.30
$59.55
52週間の値動き範囲:
$9.222
$59.55
Hims Hers Health Inc Stock (HIMS) Company Profile
名前
Hims Hers Health Inc
電話
415-851-0195
住所
2269 CHESTNUT ST, SAN FRANCISCO
HIMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
59.18 | 12.93B | 1.24B | 101.26M | 149.62M | 0.44 |
|
PG
Procter Gamble Co
|
171.02 | 401.02B | 84.35B | 15.48B | 15.47B | 6.28 |
|
UL
Unilever Plc Adr
|
55.96 | 138.40B | 64.93B | 7.15B | 0 | 2.832 |
|
CL
Colgate Palmolive Co
|
87.75 | 71.69B | 20.10B | 2.89B | 3.55B | 3.52 |
|
KMB
Kimberly Clark Corp
|
135.36 | 44.91B | 20.06B | 2.55B | 2.51B | 7.55 |
|
KVUE
Kenvue Inc
|
21.45 | 41.13B | 15.46B | 1.03B | 1.40B | 0.53 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims & Hers markets itself in a very 2025 way: by picking a fight - Fast Company
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains? - Yahoo Finance
Why Hims & Hers Health Inc. (HIMS) Went Up on Thursday - MSN
Hims & Hers jumps after RFK Jr. confirmation - Sherwood News
Hims & Hers Stock Soars on Momentum From Super Bowl Ad, RFK Confirmation - The Wall Street Journal
Hims & Hers Health (NYSE:HIMS) Reaches New 1-Year HighStill a Buy? - MarketBeat
Hims & Hers stock sees another spike in trading days after Super Bowl ad - Yahoo Finance
Medical Stocks To ConsiderFebruary 13th - MarketBeat
HIMS Stock Hits New ATH After Successful Super Bowl Ad - Markets Insider
Hims & Hers Health Faces Insider Trading Amid Stock Fluctuations - Evrim Ağacı
3 Weight-Loss Drug Stocks to Watch - Schaeffers Research
Why Novo Nordisk Stock Keeps Going Down - The Motley Fool
Hims & Hers health chief commercial officer sells $314k in stock - MSN
Hims & Hers sees 650% spike in traffic following Super Bowl ad as clash over compounded GLP-1s heats up - Fierce healthcare
Hims & Hers Health (NYSE:HIMS) Stock Quotes, Forecast and News Summary - Benzinga
Hims & Hers stock price target according to the C&H pattern - MSN
Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 7,259 Shares of Stock - MarketBeat
Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 11,581 Shares of Stock - MarketBeat
Hims Hers Health stock adds to gains amid Super Bowl ad impact - MSN
HIMS stock soars to all-time high, reaching $46.11 - MSN
Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials - Starved Rock Media
'We cannot stay silent': Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad - FiercePharma
Why Hims & Hers Terrifies Big Pharma - Barchart
Hims & Hers Super Bowl ad sparks weight-loss drug backlash - NewsNation Now
Hims & Hers Health, Inc. (HIMS): A Bull Case Theory - MSN
Hims & Hers Option Trade Offers $410 Return Or 17% Discount - MSN
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends - MarketBeat
Yousif Capital Management LLC Takes $1.79 Million Position in Hims & Hers Health, Inc. (NYSE:HIMS) - MarketBeat
Hims & Hers: Firing On All Cylinders, But Expensive - Seeking Alpha
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash - ABC News
Super Bowl ad for weight loss drug sparks backlash - Good Morning America
Hims & Hers Health Executives Sell Shares Under Trading Plans - TradingView
Hims and Hers under scrutiny after weight loss ad during Super Bowl - WHAS11.com
‘Check before you inject’: Novo bites back at Hims & Hers Super Bowl ad - MM+M Online
Hims Stock: The Future of Telehealth Investment? - Reporteros del Sur
Hims & Hers Health Stock Gains 77% YTD as Earnings Approaching - AskTraders
Hims & Hers' Super Bowl ad sparks backlash - Good Morning America
Charly AI rated this stock a BUY, 3 months ago. Now it is up 116% - substack.com
Why Hims & Hers Health (HIMS), Tempus AI (TEM) and Teladoc (TDOC) Are Up Big Today - MSN
State of Alaska Department of Revenue Invests $2.63 Million in Hims & Hers Health, Inc. (NYSE:HIMS) - MarketBeat
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight - MSN
Hims & Hers Health: Explosive Growth Potential Ahead - Seeking Alpha
Hims & Hers Health (NYSE:HIMS) Sets New 52-Week HighStill a Buy? - MarketBeat
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs - Livescience.com
Monday Morning (Advertising) Quarterback – Unprecedented Hims & Hers Super Bowl Ad Has Legislators Concerned - The National Law Review
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today - Nasdaq
Hims & Hers Stock Bounces After Super Bowl Ad - The Wall Street Journal
Ozempic, Wegovy maker responds to Hims & Hers Super Bowl ad - Modern Healthcare
On Super Bowl Sunday, ads for junk food and dessert bump up against weight-loss drugs - Marketing Brew
Hims & Hers Health Unusual Options Activity For February 10 - Benzinga
Now BIO bashes Hims & Hers as obesity ad aires - The Pharma Letter
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
1.43%
大文字化:
|
ボリューム (24 時間):